The Yale Cancer Center and Sarah Cannon Research Institute (SCRI) have finalized a deal that would allow the strategic research organization to work with the NCI-designated cancer facility and Smilow Cancer Hospital at Yale-New Haven in advancing cancer research.
The partnership will have physician scientists from SCRI and Yale Cancer Center working together to develop protocols for clinical research and strategic scientific priorities. The deal will also result in the eventual opening of a clinical trial management office at the Yale Cancer Center campus, giving Smilow Cancer Hospital the chance to jump on board by developing its own network of community-based sites to participate in the program. All that will help pave the way for assisting the Ivy League school in starting more research studies, according to an SCRI statement.
"This collaboration allows top scientific thought leaders in cancer to come together to develop enhanced clinical trial opportunities and increase access for patients to the latest treatments available," said Howard "Skip" Burris, chief medical officer and executive director of drug development for SCRI, in a statement.
- see the release